Systemic efficacy with oncolytic virus therapeutics: Clinical proof-of-concept and future directions

Ta Chiang Liu; David Kirn

doi:10.1158/0008-5472.CAN-06-2871

Systemic efficacy with oncolytic virus therapeutics: Clinical proof-of-concept and future directions

Ta Chiang Liu, David Kirn

Research output: Contribution to journal › Review article › peer-review

104 Scopus citations

Abstract

Oncolytic viruses that can destroy cancer cells have been engineered in a variety of ways with the aim of improving their selectivity and efficacy. Here, we review data from clinical investigations of these virotherapeutic agents, specifically those that have shown systemic efficacy: vaccinia, measles, mumps, viruses, Newcastle disease virus, and reovirus. Further directions for optimizing i.v. delivery and efficacy are discussed.

Original language	English
Pages (from-to)	429-432
Number of pages	4
Journal	Cancer research
Volume	67
Issue number	2
DOIs	https://doi.org/10.1158/0008-5472.CAN-06-2871
State	Published - Jan 15 2007

Access to Document

10.1158/0008-5472.CAN-06-2871

Cite this

@article{09321a2592834ebcb2fa4a3575e3118b,

title = "Systemic efficacy with oncolytic virus therapeutics: Clinical proof-of-concept and future directions",

abstract = "Oncolytic viruses that can destroy cancer cells have been engineered in a variety of ways with the aim of improving their selectivity and efficacy. Here, we review data from clinical investigations of these virotherapeutic agents, specifically those that have shown systemic efficacy: vaccinia, measles, mumps, viruses, Newcastle disease virus, and reovirus. Further directions for optimizing i.v. delivery and efficacy are discussed.",

author = "Liu, {Ta Chiang} and David Kirn",

year = "2007",

month = jan,

day = "15",

doi = "10.1158/0008-5472.CAN-06-2871",

language = "English",

volume = "67",

pages = "429--432",

journal = "Cancer research",

issn = "0008-5472",

number = "2",

}

TY - JOUR

T1 - Systemic efficacy with oncolytic virus therapeutics

T2 - Clinical proof-of-concept and future directions

AU - Liu, Ta Chiang

AU - Kirn, David

PY - 2007/1/15

Y1 - 2007/1/15

N2 - Oncolytic viruses that can destroy cancer cells have been engineered in a variety of ways with the aim of improving their selectivity and efficacy. Here, we review data from clinical investigations of these virotherapeutic agents, specifically those that have shown systemic efficacy: vaccinia, measles, mumps, viruses, Newcastle disease virus, and reovirus. Further directions for optimizing i.v. delivery and efficacy are discussed.

AB - Oncolytic viruses that can destroy cancer cells have been engineered in a variety of ways with the aim of improving their selectivity and efficacy. Here, we review data from clinical investigations of these virotherapeutic agents, specifically those that have shown systemic efficacy: vaccinia, measles, mumps, viruses, Newcastle disease virus, and reovirus. Further directions for optimizing i.v. delivery and efficacy are discussed.

UR - http://www.scopus.com/inward/record.url?scp=33846686516&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-2871

DO - 10.1158/0008-5472.CAN-06-2871

M3 - Review article

C2 - 17234747

AN - SCOPUS:33846686516

SN - 0008-5472

VL - 67

SP - 429

EP - 432

JO - Cancer research

JF - Cancer research

IS - 2

ER -

Systemic efficacy with oncolytic virus therapeutics: Clinical proof-of-concept and future directions

Abstract

Access to Document

Other files and links

Fingerprint

Cite this